QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: Plasma-Derived Medicinal Products—Classification and Pharmacovigilance

Test your understanding of the concepts covered by Plasma-Derived Medicinal Products: Classification and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 An increase in reports follows a widely publicised safety concern, but no corresponding change in clinical presentation or exposure is evident. What should signal assessors consider?

Publicity or increased awareness may have stimulated reporting without proving increased clinical risk The increase confirms a manufacturing defect The reports should be excluded because stimulated reporting is never informative The product should automatically be classified as having a new identified risk

Question 2 of 10 Which scenario most clearly illustrates why background disease must be considered in aggregate evaluation?

A product is available in only one presentation A coagulation factor is used in populations with different underlying haemostatic disorders and indications A batch number is recorded in an administration log A manufacturing process has a validated virus-inactivation step

Question 3 of 10 Which record set would best support reconstruction of the reasoning behind a suspected product-quality or infectious-safety assessment?

Only the final conclusion Only the product label and standard operating procedure Case data, exposure and batch information, quality findings, alternative explanations, uncertainty and the rationale for actions Only the number of reports received during the period

Question 4 of 10 What is the most appropriate organisational response when a clinical report raises a plausible product-quality hypothesis?

Pharmacovigilance should close the case until quality completes its investigation Quality should determine clinical causality without pharmacovigilance input Pharmacovigilance and quality should retain distinct responsibilities while conducting a coordinated assessment Regulatory affairs should independently replace both functions

Question 5 of 10 A patient receiving lifelong replacement therapy develops bleeding. Which principle should guide the assessment?

All bleeding after factor treatment is automatically an adverse drug reaction The event should be assessed using treatment adequacy, timing, interruption, disease context and possible inhibitor development Bleeding cannot be treatment-related in patients receiving replacement therapy Only the product batch is relevant to the assessment

Question 6 of 10 Why is benefit–risk assessment especially important for some plasma-derived products used for protein or immune-function replacement?

Replacement products have no adverse effects The therapeutic benefit may be substantial, so safety concerns must be weighed against disease severity, treatment necessity and alternatives Benefit–risk assessment applies only before authorisation Alternative products are always clinically equivalent

Question 7 of 10 What is the most appropriate purpose of traceability controls across prescribing, dispensing and administration?

To reconstruct clinically meaningful exposure when investigating a safety question To prove causality for any event occurring after treatment To eliminate the need for medical assessment To require complete reconstruction of every manufacturing detail for every case

Question 8 of 10 Which statement best describes the relationship between general GVP requirements and plasma-derived product surveillance?

Plasma-derived products require an entirely separate pharmacovigilance system General GVP processes apply, supplemented by product-specific understanding and controls Only quality legislation applies because the products originate from plasma General GVP is unnecessary when a plasma master file exists

Question 9 of 10 A patient switches from a plasma-derived coagulation factor to a recombinant product and later experiences loss of efficacy. Which information is most important for interpretation?

Only the name of the most recently administered product The chronology of exposure to each product and relevant treatment history The total number of adverse events reported for all coagulation factors Whether the products have the same therapeutic function

Question 10 of 10 Which conclusion is most consistent with the article's overall pharmacovigilance model?

Source material determines causality in clinical cases Manufacturing controls make clinical surveillance largely redundant Effective surveillance links source and product identity, exposure, clinical evidence, quality information and appropriate action Class-level information should always replace individual-product assessment

Knowledge Assessment: Plasma-Derived Medicinal Products—Classification and Pharmacovigilance

Cookie Settings